ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,939.75
1.24%
US Tech 100
20,853.60
1.39%
다우존스 지수
42,899.78
1.32%
Bitcoin
96,911.95
-0.56%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Xilio Therapeutics Inc (XLO)

  7. Xilio Therapeutics Inc (XLO) 뉴스

XLO

Xilio Therapeutics (XLO)

Xilio Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:XLO
일자시간출처헤드라인심볼기업
2024/12/1921:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
2024/12/1921:30GlobeNewswire Inc.Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI NASDAQ:XLOXilio Therapeutics Inc
2024/12/1621:30GlobeNewswire Inc.Xilio Therapeutics Appoints Caroline Hensley as Chief Legal OfficerNASDAQ:XLOXilio Therapeutics Inc
2024/12/0406:30GlobeNewswire Inc.Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:XLOXilio Therapeutics Inc
2024/11/0723:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XLOXilio Therapeutics Inc
2024/11/0723:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
2024/11/0723:15GlobeNewswire Inc.Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid TumorsNASDAQ:XLOXilio Therapeutics Inc
2024/11/0723:05GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
2024/10/3022:01GlobeNewswire Inc.Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
2024/10/0422:05GlobeNewswire Inc.Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
2024/10/0306:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
2024/10/0305:15GlobeNewswire Inc.Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:XLOXilio Therapeutics Inc
2024/09/2810:36Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:XLOXilio Therapeutics Inc
2024/09/2810:36Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:XLOXilio Therapeutics Inc
2024/09/2810:36Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:XLOXilio Therapeutics Inc
2024/09/2810:36Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:XLOXilio Therapeutics Inc
2024/09/2810:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
2024/09/2810:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
2024/09/2810:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
2024/09/2810:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
2024/09/1405:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
2024/08/2905:01GlobeNewswire Inc.Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:XLOXilio Therapeutics Inc
2024/08/0820:51Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XLOXilio Therapeutics Inc
2024/08/0820:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
2024/08/0820:30GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
2024/08/0709:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
2024/06/1805:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
2024/06/1805:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
2024/06/1805:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
2024/06/1405:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
 검색 관련기사 보기:NASDAQ:XLO

최근 히스토리

USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
BAC
Bank of America
CCOM
SILVER
SILVER
CCOM
US30
US 30
FX
USDGBP
US Dollar vs Sterling
COIN
AVAXUSD
Avalanche
NYSE
AXP
American Express
NASDAQ
MSFT
Microsoft
SPI
SP500
S&P 500
PM
XAUUSD
Gold vs US Dollar
NASDAQ
AMZN
Amazon.com
COIN
SOLUSD
Solana
CCOM
US100
US Tech 100
AMEX
XLV
Health Care Select Sector
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유